Jenscare Scientific (HKG:9877) said the success rate for its LuX-Valve Plus transcatheter tricuspid valve replacement device, tested during a 30-day global follow-up study, reached 97%, according to a Friday filing with the Hong Kong bourse.
The study, performed on 161 patients in 20 centers worldwide, also showed good safety and performance of the device, the filing said.
Meanwhile, Jenscare's JensClip transcatheter mitral valve repair system showed a device operation success rate of 95% during its one-year follow-up study in China, the filing said.
Jenscare performed the study on 114 patients with an average age of 71 years across 18 centers in China.
Jenscare presented the results of the 30-day study during the EuroPCR 2025 in Paris.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.